Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Innovata Biomed in Japanese drug delivery deal:

This article was originally published in Clinica

Executive Summary

Innovata Biomed (IB), the respiratory drug delivery subsidiary of Warrington, UK-based ML Laboratories, has signed an agreement with Japanese healthcare company Otsuka Pharmaceutical Co. Under the terms of the agreement, the Tokyo-based company has been given an exclusive licence to market its asthma treatment product, Meptin, in IB's "Clickhaler" dry powder inhaler in Japan and Spain. In return, IB will receive milestone payments and will supply the inhalers to Otsuka. "We strongly believe that this combinations will provide asthma patients with the most reliable, easy-to-use solution," said Otsuka's operations officer Masuhiro Yoshitake. Paul Bellington, managing director of St. Albans-based IB, added: "Today's announcement supports Innovata Biomed's position as one of the leading independent providers of respiratory drug delivery technologies to the pharmaceuticals industry."

You may also be interested in...

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

Tiofarma Admits Involvement On UK Fludrocortisone

Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts